Commentary on Hey and Kimmelman

Ellenberg SS Fleming TR DeMets DL . Data monitoring committees in clinical trials: a practical perspective. Chichester; Hoboken, NJ: John Wiley & Sons, 2002, p. xiii, 191 pp.

Marquis D . Leaving therapy to chance. Hastings Cent Rep 1983; 13: 40–47.

Lipsky AM Lewis RJ . Response-adaptive decision-theoretic trial design: operating characteristics and ethics. Stat Med 2013; 32: 3752–3765.

Karrison TG Huo DZ Chappell R . A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials 2003; 24: 506–522.

Palmer CR Rosenberger WF . Ethics and practice: alternative designs for phase III randomized clinical trials. Control Clin Trials 1999; 20: 172–186.

Rosenberger WF Lachin JM . The use of response-adaptive designs in clinical trials. Control Clin Trials 1993; 14: 471–484.

Hey S Kimmelman J . Are outcome-adaptive allocation trials ethical? Clin Trials, 2015, 12: 102–106.

Emanuel EJ Wendler D Grady C . What makes clinical research ethical? JAMA 2000; 283: 2701–2711.

Green SJ Fleming TR O’Fallon JR . Policies for study monitoring and interim reporting of results. J Clin Oncol 1987; 5: 1477–1484.

Miller FG Joffe S . Equipoise and the dilemma of randomized clinical trials. New Engl J Med 2011; 364: 476–480.